Previous Close | 168.51 |
Open | 168.73 |
Bid | 168.88 x 800 |
Ask | 172.90 x 800 |
Day's Range | 167.41 - 171.14 |
52 Week Range | 151.03 - 201.92 |
Volume | |
Avg. Volume | 2,739,759 |
Market Cap | 77.476B |
Beta (5Y Monthly) | 0.87 |
PE Ratio (TTM) | 33.37 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 1.73 (1.03%) |
Ex-Dividend Date | Apr 18, 2024 |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for ZTS
The European Commission announced on Tuesday that it has initiated an investigation into whether Zoetis Inc (NYSE: ZTS hindered the market launch of a competing pain medication for dogs. Zoetis’ Librela is the first and only monoclonal antibody medicine approved in Europe to treat pain associated with osteoarthritis in dogs. The medicine is administered monthly and offers a novel pain relief option, particularly relevant for older dogs. The European Commission said that Zoetis, while working on
EU antitrust regulators have started an investigation into whether Zoetis blocked the market launch of a rival pain medicine for dogs, the European Commission said on Tuesday, a move that could result in a hefty fine for the U.S. pet products maker. Antitrust regulators on both sides of the Atlantic have recently cracked down on Big Tech and Big Pharma acquiring start-ups or small rivals in order to shut them down in what is known as killer acquisitions. Zoetis' Librela is currently the first and only monoclonal antibody medicine approved in Europe to treat pain associated with osteoarthritis in dogs.
(Reuters) -EU antitrust regulators have started an investigation into whether Zoetis blocked the market launch of a rival pain medicine for dogs, the European Commission said on Tuesday, a move that could result in a hefty fine for the U.S. pet products maker. Antitrust regulators on both sides of the Atlantic have recently cracked down on Big Tech and Big Pharma acquiring start-ups or small rivals in order to shut them down in what is known as killer acquisitions. Zoetis' Librela is currently the first and only monoclonal antibody medicine approved in Europe to treat pain associated with osteoarthritis in dogs.